Tilray Brands Inc
2HQ
Company Profile
Business description
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. USA exposure consists of CBD products and alcohol.
Contact
265 Talbot Street West
LeamingtonONN8H 5L4
CANT: +1 844 845-7291
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 May 2026
Employees
2,842
Stocks News & Analysis
stocks
Palantir earnings: Blockbuster growth amid high expectations
We raise our fair value estimate off the back of earnings.
stocks
ResMed earnings: Solid showing from ASX healthcare winner
Strong demand growth and improved profit margins lead to a strong result from the sleep apnea device firm.
stocks
Is this the $80 billion elephant Warren Buffett has been waiting for?
Morningstar’s Greg Warren says Berkshire may have little choice but to take a hard look at this huge potential acquisition.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,088.20 | 59.40 | 0.66% |
| CAC 40 | 7,621.04 | 10.97 | -0.14% |
| DAX 40 | 23,846.07 | 88.38 | 0.37% |
| Dow JONES (US) | 44,111.74 | 61.90 | -0.14% |
| FTSE 100 | 9,142.73 | 14.43 | 0.16% |
| HKSE | 24,902.53 | 169.08 | 0.68% |
| NASDAQ | 20,916.55 | 137.03 | -0.65% |
| Nikkei 225 | 40,529.12 | 20.42 | -0.05% |
| NZX 50 Index | 12,905.12 | 28.08 | 0.22% |
| S&P 500 | 6,299.19 | 30.75 | -0.49% |
| S&P/ASX 200 | 8,823.50 | 53.10 | 0.61% |
| SSE Composite Index | 3,617.60 | 34.29 | 0.96% |